Malignant Bone Tumor, Radiotherapy, Spinal Metastases, Spinal Tumor, Surgery
Conditions
Keywords
Total enbloc spondylectomy, Oligometastases
Brief summary
The purpose of this clinical trial is to explore the impact of En bloc surgery and separation surgery combined with radiation therapy on the prognosis and survival of patients with spinal oligometastatic cancer, describe the clinical results, and optimize future treatment goals
Detailed description
Patients with oligometastatic diseases have been shown to have better prognosis than those with multiple metastatic diseases, and some patients have achieved long-term survival, thus being considered to benefit from more aggressive treatment. Active local treatment, including surgery and/or targeted radiotherapy, such as Stereotactic Radiosurgery (SRS) and Stereotactic body radiotherapy (SBRT), can be performed before or after systemic treatment. For both primary and oligometastatic tumors, radical treatment should be considered in order to achieve better survival and prognosis. The current research has explored the different effects of oligometastatic disease status on the prognosis of various cancers. However, there is currently no clear clinical or experimental confirmation of the impact on the survival and treatment outcomes of patients with oligometastatic spinal cancer. The purpose of this clinical trial is to explore the impact of En bloc hand surgery and separation surgery combined with radiotherapy on the prognosis and survival of patients with oligometastatic spinal cancer, Describe clinical outcomes and optimize future treatment goals
Interventions
PROCEDUREtotal en bloc spondylectomy
Total enbloc resection (TES) is one of the most challenging surgeries in spinal surgery and a classic surgical method. It not only relieve spinal cord compression and delays tumor recurrence, but also prolongs patient survival, significantly reduces hand surgery trauma, and improves surgical safety. However, for cases with extensive tumor invasion, methods such as separation surgery should be used to relieve spinal cord nerve compression, rebuild spinal stability, and provide conditions for postoperative radiotherapy.
Sponsors
Peking University Third Hospital
Peking University People's Hospital
Henan Cancer Hospital
First Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University
Zhejiang University
Tianjin Hospital
The First Affiliated Hospital of Nanchang University
The Third Affiliated Hospital of Southern Medical University
Shanghai Changzheng Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* 1\) Be able to sign written informed consent. * 2\) Age range from 18 to 75 years old, regardless of gender. * 3\) Within conservative treatment, the patient still has uncontrollable pain, metastatic cancer lesions that still progress, spinal instability/potential instability, or symptoms of spinal cord/nerve compression. * 4\) After the patient underwent Positron Emission Tomography-Computed Tomography (PET-CT) examination, it was indicated that there were no more than 3 metastatic organs and no more than 5 metastatic lesions in the whole body of cancer. Among them, there was at least 1 spinal metastasis and at most 5 spinal metastases. * 5\) Imaging examinations (enhanced MRI, enhanced CT, X-ray) indicate the presence of spinal metastasis. * 6\) The expected survival period is ≥ 6 months. * 7)No other surgical contraindications
Exclusion criteria
* 1\) Primary tumors of the spine or multiple tumors of the body, with\>3 metastatic organs and\>5 metastatic sites. * 2\) Previously underwent spinal surgery, or received radiotherapy for the responsible segment of this treatment. * 3\) Severe heart, lung, liver, kidney or other diseases affecting the surgery. * 4\) Having cognitive impairment, sensory aphasia, and inability to understand basic instructions. * 5\) Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment. * 6\) Infectious diseases. * 7\) Refuse to follow up or participate. * 8\) The researchers determine that the patients are not suitable for enrollment this clinical trail.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival(OS) | after surgery until death due to primary disease or responsible segment | On the basis of maintaining systemic treatment, compare the overall survival period of En bloc surgery and separation surgery combined with radiation therapy for patients with spinal oligometastatic cancer, after surgery until death due to primary disease or responsible segment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local Control Rate(LRC) | a 20% increase in the total diameter of the target lesion observed on imaging from the beginning of the patient's current treatment to baseline. | Based on the Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1), it is defined as a 20% increase in the total diameter of the target lesion observed on imaging from the beginning of the patient's current treatment to baseline. |
| Progression-Free Survival(PFS) | The period between the patient receiving this treatment and observing local progression or death from any cause. | The period between the patient receiving this treatment and observing local progression or death from any cause. Based on the changes in patient imaging and neurological function, comprehensively evaluate whether the local lesion of the spine is progressing. |
| Brief Pain inventory | 1 day before surgery, 2 weeks after surgery, 1 month after surgery, 3 months after surgery, 6 months after surgery, and 12 months after surgery. | Use the Brief Pain Inventory (BPI) to score the pain levels 1 day before surgery, 2 weeks after surgery, 1 month after surgery, 3 months after surgery, 6 months after surgery, and 12 months after surgery. |
| EORTC Quality of Life Questionnaire - Core 30 | 1 day before surgery, 2 weeks after surgery, 1 month after surgery, 3 months after surgery, 6 months after surgery, and 12 months after surgery | Evaluate the quality of life of patients 1 day before surgery, 2 weeks after surgery, 1 month after surgery, 3 months after surgery, 6 months after surgery, and 12 months after surgery using EORTC Quality of Life Questionnaire - Core 30 |
| Complication | 1 month, 3 months, 6 months, and 12 months after surgery. | The incidence of vertebral compression fractures: X-ray examination of the surgical area was performed on the first day, within 3 months, within 6 months, and within 12 months respectively. Wound complications: Erythrocyte Sedimentation Rate (ESR) and C-reactive protein tests were performed on the first day after surgery. Observe and record the incidence of incision infection, incision non healing, and the need for debridement within 1 month after surgery. Other complications: Observe whether the patient experiences bleeding, pulmonary infection, or pulmonary embolism within one month after treatment. |
Countries
China
Contacts
Primary ContactJianru Xiao, Doctor
Backup ContactWei Xu, Doctor
Outcome results
None listed